Top

Intensive Care Medicine

Published in:

01-09-2015 | Original

Resuscitation fluid use in Australian and New Zealand Intensive Care Units between 2007 and 2013

Authors: N. E. Hammond, C. Taylor, M. Saxena, B. Liu, S. Finfer, P. Glass, I. Seppelt, L. Willenberg, J. Myburgh

Published in: Intensive Care Medicine | Issue 9/2015

Abstract

Introduction

Recent evidence indicates that the choice of intravenous fluids may affect outcomes in critically ill patients.

Methods

We recorded the administration of resuscitation fluids in patients admitted to Australian and New Zealand adult intensive care units (ICUs) for a 24-h period at 6 time points between 2007 and 2013. Changes in patterns of fluid use over this period were determined using regression analyses.

Results

Of the 2825 patients admitted to the 61 ICUs on the 6 study days, 754 (26.7 %) patients received fluid resuscitation. Of those receiving fluid resuscitation, the proportion of patients receiving crystalloid significantly increased from 28.9 % (41/142) in 2007 to 50.5 % (48/95) in 2013 (adjusted odds ratio (OR) 2.93; 95 % confidence intervals (CI) 1.35–6.33; p = 0.006); of these, the proportion of patients receiving buffered salt solutions significantly increased from 4.9 % (7/142) in 2007 to 31.6 % (30/95) in 2013 (OR 7.00; 95 % CI 2.14–22.92; p = 0.001). The use of colloids significantly decreased from 59.9 % (85/142) in 2007 to 42.1 % (40/95) in 2013 (adjusted OR 0.34; 95 % CI 0.16–0.74; p = 0.007) due to a significant decrease in the proportion of patients receiving gelatin; 28.9 % (41/142) to 2.1 % (2/95) (OR 0.10; 95 % CI 0.03–0.29; p ≤ 0.001).

Conclusion

Fluid resuscitation practice in Australia and New Zealand adult ICUs has changed over the 6-year study period. Crystalloid use increased primarily due to an increase in the use of buffered salt solutions while overall the use of colloid has decreased.

Available only for authorised users

Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D et al (2010) Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 14:R185PubMedCentralCrossRefPubMed

SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256CrossRef

Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N et al (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139CrossRefPubMed

Myburgh J, Finfer S, Bellomo R, Billot L, Cass A, Gattas D et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911CrossRefPubMed

Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A et al (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134CrossRefPubMed

SAFE Study Investigators (2007) Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 357:874–884CrossRef

The SAFE Study Investigators (2011) Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 37:86–96CrossRef

Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 10:1412–1421CrossRef

Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J et al (2012) Assessment of hemodynamic efficacy and safety of 6 % hydroxyethyl starch 130/0.4 vs. 0.9 % NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16:R94PubMedCentralCrossRefPubMed

10.

Perel P, Roberts I, Ker K (2013) Colloids versus crystalloids for fluid resuscitation in critically ill patients (review). Cochrane Database System Rev 2:CD000567

11.

Mutter TC, Ruth CA, Dart AB (2013) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 7:CD007594PubMed

12.

Haase N, Perner A, Inkeri Hennings L, Siegemund M, Lauridsen B, Wetterslev M et al (2013) Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839PubMedCentralCrossRefPubMed

13.

Zarychanski R, Abou-Setta A, Turgeon A, Houston B, McIntyre L, Marshall J et al (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688CrossRefPubMed

14.

Gattas D, Dan A, Myburgh J, Billot L, Lo S, Finfer S et al (2013) Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4) and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacment therapy. Intensive Care Med 39:558–568CrossRefPubMed

15.

Powell-Tuck J, Gosling P, Lobo D, Allison S, Carlson G, Gore M et al (2011) British Consensus Guidelines on intravenous fluid therapy for adult surgical patients (GIFTASUP). http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf. Accessed 22 May 2015

16.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228CrossRefPubMed

17.

FDA (2005) Safety of albumin administration in critically ill patients. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/BloodSafety/ucm095539.htm. Accessed 22 May 2015

18.

EMA (2013) PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144448.pdf. Accessed 22 May 2015

19.

FDA (2013) Hydroxyethyl starch solutions: FDA safety communication—boxed warning on increased mortality and severe renal injury and risk of bleeding. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm358349.htm. Accessed 22 May 2015

20.

MHRA (2013) Hydroxyethyl starch (HES) products—increased risk of renal dysfunction and mortality. https://www.gov.uk/drug-device-alerts/drug-alert-hydroxyethyl-starch-hes-products-increased-risk-of-renal-dysfunction-and-mortality. Accessed 22 May 2015

21.

TGA (2013) Hydroxyethyl starch (Voluven and Volulyte) and increased risk of mortality. http://www.tga.gov.au/monitoring-communication/hydroxyethyl-starch-voluven-and-volulyte-and-increased-risk-mortality. Accessed 22 May 2015

22.

FDA (2013) FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm. Accessed 22 May 2015

23.

Yunos NM, Bellomo R, Glassford N, Sutcliffe H, Lam Q, Bailey M (2014) Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis. Intensive Care Med 41:257–264CrossRefPubMed

24.

Yunos N, Bellomo R, Hegarty C, Story D, Ho L, Bailey M (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566–1572CrossRefPubMed

25.

Shaw A, Bagshaw S, Goldstein S et al (2012) Major complications, mortality, and resource utilization after open abdominal surgery: 0.9 % saline compared to plasma-lyte. Ann Surg 255:821–829CrossRefPubMed

26.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381PubMedCentralCrossRefPubMed

27.

Knaus W, Draper E, Wagner D, Zimmerman J (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829CrossRefPubMed

28.

Miletin M, Stewart T, Norton P (2002) Influences on physicians’ choices of intravenous colloids. Intensive Care Med 28:917–924CrossRefPubMed

29.

Schortgen F, Deye N, Brochard L, CRYCO Study Group (2004) Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 30:2222–2229CrossRefPubMed

30.

The FLUID study Investigators (2008) Preference for colloid use in Scandinavian intensive care units. Acta Anaesthesiol Scand 52:750–758CrossRef

31.

Zhou F, Peng Z, Bishop J, Cove M, Singbartl K, Kellum J (2014) Effects of fluid resuscitation with 0.9 % saline versus a balanced electrolyte solution on acute kidney injury in a rat model of sepsis. Crit Care Med 42:e270–e278PubMedCentralCrossRefPubMed

32.

Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D et al (2011) The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med 39:2419–2424CrossRefPubMed

33.

Raghunathan K, Shaw A, Nathanson B, Stürmer T, Brookhart A, Stefan M et al (2014) Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med 42:1585–1591CrossRefPubMed

34.

The National Heart L, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trial Network (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–2575CrossRef

35.

Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259–265CrossRefPubMed

Title: Resuscitation fluid use in Australian and New Zealand Intensive Care Units between 2007 and 2013
Authors: N. E. Hammond
C. Taylor
M. Saxena
B. Liu
S. Finfer
P. Glass
I. Seppelt
L. Willenberg
J. Myburgh
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 9/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-015-3878-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Resuscitation fluid use in Australian and New Zealand Intensive Care Units between 2007 and 2013

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2015

A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators

Fluid resuscitation in ICU patients: quo vadis?

Is sedation safe and beneficial in patients receiving NIV? Yes

The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study)

Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis

Erratum to: Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial